Supernus Pharmaceuticals, Inc.(SUPN)Earnings, Financials & Key Ratios

SUPN•NASDAQ

$51.45

$2.96B mkt cap·Price updated May 6, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryTherapy-focused branded biopharma

AboutSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.Show more

Revenue$719M+8.6%
EBITDA$55M-66.3%
Net Income-$39M-152.2%
EPS (Diluted)-0.68-151.5%
Gross Margin89.63%+1.6%
EBITDA Margin7.61%-68.9%
Operating Margin-5.13%-141.6%
Net Margin-5.36%-148.0%
ROE-3.68%-148.7%
ROIC-2.8%-143.2%
Debt/Equity0.04+16.6%

Technical→

SUPN Key Insights

Supernus Pharmaceuticals, Inc. (SUPN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak 3Y average ROE of 1.3%

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

SUPN Price & Volume

Supernus Pharmaceuticals, Inc. (SUPN) stock price & volume — 10-year historical chart

Loading chart...

SUPN Growth Metrics

Supernus Pharmaceuticals, Inc. (SUPN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years17.41%

5 Years6.68%

3 Years2.52%

TTM16.29%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-146.87%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-146.09%

Return on Capital

10 Years13.95%

5 Years2.88%

3 Years1.34%

Last Year-3.37%

SUPN Recent Earnings

Supernus Pharmaceuticals, Inc. (SUPN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)

Q2 2026Latest

May 5, 2026

EPS

$0.59

Est $0.28

+110.7%

Revenue

$208M

Est $193M

+7.7%

Q1 2026

Feb 24, 2026

EPS

$0.92

Est $0.28

+228.6%

Revenue

$212M

Est $195M

+8.4%

Q4 2025

Nov 4, 2025

EPS

$1.01

Est $0.82

+23.2%

Revenue

$192M

Est $195M

-1.3%

Q3 2025

Aug 5, 2025

EPS

$0.91

Est $0.47

+93.6%

Revenue

$165M

Est $168M

-1.7%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$0.59vs $0.28+110.7%	$208Mvs $193M+7.7%
Q1 2026	Feb 24, 2026	$0.92vs $0.28+228.6%	$212Mvs $195M+8.4%
Q4 2025	Nov 4, 2025	$1.01vs $0.82+23.2%	$192Mvs $195M-1.3%
Q3 2025	Aug 5, 2025	$0.91vs $0.47+93.6%	$165Mvs $168M-1.7%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
PCRXPacira BioSciences, Inc.Direct Competitor	931.85M	23.69	148.06	3.63%	1.27%	1.31%	0.66
ACADACADIA Pharmaceuticals Inc.Direct Competitor	3.68B	21.48	9.38	11.87%	36.49%	41.9%	0.04
INVAInnoviva, Inc.Direct Competitor	1.91B	22.52	6.82	18.52%	118.91%	46.47%	0.23
PRGOPerrigo Company plcDirect Competitor	1.69B	12.26	-1.19	-2.75%	-43.5%	-50.65%	1.35
LNTHLantheus Holdings, Inc.Direct Competitor	5.61B	86.15	25.26	0.5%	15.15%	20.58%	0.00
HRMYHarmony Biosciences Holdings, Inc.Direct Competitor	1.89B	32.78	12.10	21.51%	18.27%	18.24%	0.02
AXSMAxsome Therapeutics, Inc.Direct Competitor	11.46B	222.63	-60.50	65.55%	-26.59%	-260.01%	2.73
NKTRNektar TherapeuticsProduct Competitor	1.67B	85.09	-8.75	-43.89%	-192.87%	-356.81%	0.95

Compare SUPN vs Peers

Supernus Pharmaceuticals, Inc. (SUPN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PCRX

Most directly comparable listed peer for SUPN.

Scale Benchmark

vs MCK

Larger-name benchmark to compare SUPN against a more recognizable public peer.

Peer Set

Compare Top 5

vs PCRX, ACAD, INVA, PRGO

SUPN Income Statement

Supernus Pharmaceuticals, Inc. (SUPN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	302.24M	408.9M	392.75M	520.4M	579.77M	667.24M	607.52M	661.82M	718.95M	776.83M
Revenue Growth %	40.57%	35.29%	-3.95%	32.5%	11.41%	15.09%	-8.95%	8.94%	8.63%	16.29%
Cost of Goods Sold	15.21M	15.36M	16.66M	52.46M	75.06M	87.22M	83.78M	77.91M	74.56M	82.19M
COGS % of Revenue	5.03%	3.76%	4.24%	10.08%	12.95%	13.07%	13.79%	11.77%	10.37%	-
Gross Profit	287.02M▲ 0%	393.54M▲ 37.1%	376.1M▼ 4.4%	467.94M▲ 24.4%	504.71M▲ 7.9%	580.02M▲ 14.9%	523.74M▼ 9.7%	583.91M▲ 11.5%	644.39M▲ 10.4%	694.64M▲ 0%
Gross Margin %	94.97%	96.24%	95.76%	89.92%	87.05%	86.93%	86.21%	88.23%	89.63%	89.42%
Gross Profit Growth %	41.38%	37.11%	-4.43%	24.42%	7.86%	14.92%	-9.7%	11.49%	10.36%	-
Operating Expenses	187.48M	249.1M	227.52M	294.24M	418.69M	533.89M	529.01M	502.25M	681.25M	737.24M
OpEx % of Revenue	62.03%	60.92%	57.93%	56.54%	72.22%	80.02%	87.08%	75.89%	94.76%	-
Selling, General & Admin	137.91M	159.89M	158.43M	200.68M	304.76M	377.22M	336.36M	335.78M	485.56M	520.79M
SG&A % of Revenue	45.63%	39.1%	40.34%	38.56%	52.56%	56.53%	55.37%	50.74%	67.54%	-
Research & Development	49.58M	89.21M	69.1M	75.96M	90.47M	74.55M	91.59M	108.8M	106.23M	118.75M
R&D % of Revenue	16.4%	21.82%	17.59%	14.6%	15.6%	11.17%	15.08%	16.44%	14.78%	-
Other Operating Expenses	0	0	0	17.6M	23.46M	82.12M	101.06M	57.67M	89.46M	4M
Operating Income	99.54M▲ 0%	144.44M▲ 45.1%	148.57M▲ 2.9%	173.7M▲ 16.9%	86.03M▼ 50.5%	46.12M▼ 46.4%	-5.27M▼ 111.4%	81.67M▲ 1649.9%	-36.86M▼ 145.1%	-42.6M▲ 0%
Operating Margin %	32.93%	35.33%	37.83%	33.38%	14.84%	6.91%	-0.87%	12.34%	-5.13%	-5.48%
Operating Income Growth %	83.6%	45.11%	2.86%	16.91%	-50.47%	-46.39%	-111.42%	1649.93%	-145.14%	-
EBITDA	107.67M	151.51M	158.8M	191.84M	118.62M	131.67M	79.59M	162.08M	54.7M	28.58M
EBITDA Margin %	35.63%	37.05%	40.43%	36.86%	20.46%	19.73%	13.1%	24.49%	7.61%	3.68%
EBITDA Growth %	90.18%	40.71%	4.81%	20.81%	-38.16%	11%	-39.55%	103.64%	-66.25%	-81.51%
D&A (Non-Cash Add-back)	8.13M	7.06M	10.22M	18.14M	32.59M	85.54M	84.86M	80.41M	91.56M	71.18M
EBIT	99.54M	144.44M	170.19M	192.4M	96.6M	67.81M	5.18M	97.87M	-49.03M	-46.43M
Net Interest Income	1.08M	-4.27M	-1.08M	-5.05M	-12.85M	14.62M	8.04M	16.2M	13.25M	8.83M
Interest Income	2.65M	13.84M	21.62M	18.7M	10.57M	21.69M	10.45M	16.2M	13.25M	8.83M
Interest Expense	1.57M	18.11M	22.71M	23.75M	23.42M	7.07M	2.42M	0	0	0
Other Income/Expense	1.08M	-4.27M	-1.08M	-5.05M	-12.85M	14.62M	8.04M	16.2M	-12.17M	-6.55M
Pretax Income	100.62M▲ 0%	140.18M▲ 39.3%	147.49M▲ 5.2%	168.65M▲ 14.3%	73.17M▼ 56.6%	60.74M▼ 17.0%	2.77M▼ 95.4%	97.87M▲ 3434.5%	-49.03M▼ 150.1%	-49.15M▲ 0%
Pretax Margin %	33.29%	34.28%	37.55%	32.41%	12.62%	9.1%	0.46%	14.79%	-6.82%	-6.33%
Income Tax	43.33M	29.18M	34.43M	41.7M	19.75M	32K	1.45M	24M	-10.48M	-20.13M
Effective Tax Rate %	43.07%	20.82%	23.35%	24.72%	26.99%	0.05%	52.47%	24.53%	21.37%	40.96%
Net Income	57.28M▲ 0%	110.99M▲ 93.8%	113.06M▲ 1.9%	126.95M▲ 12.3%	53.42M▼ 57.9%	60.71M▲ 13.6%	1.32M▼ 97.8%	73.86M▲ 5512.8%	-38.55M▼ 152.2%	-29.02M▲ 0%
Net Margin %	18.95%	27.14%	28.79%	24.39%	9.21%	9.1%	0.22%	11.16%	-5.36%	-3.74%
Net Income Growth %	-37.2%	93.76%	1.86%	12.29%	-57.92%	13.64%	-97.83%	5512.84%	-152.19%	-146.87%
Net Income (Continuing)	57.28M	110.99M	113.06M	126.95M	53.42M	60.71M	1.32M	73.86M	-38.55M	-29.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	1.08▲ 0%	2.05▲ 89.8%	2.10▲ 2.4%	2.36▲ 12.4%	0.98▼ 58.5%	1.04▲ 6.1%	0.02▼ 97.7%	1.32▲ 5469.6%	-0.68▼ 151.5%	-0.50▲ 0%
EPS Growth %	-38.64%	89.81%	2.44%	12.38%	-58.47%	6.12%	-97.72%	5469.62%	-151.52%	-146.09%
EPS (Basic)	1.13	2.13	2.16	2.41	1.01	1.13	0.02	1.34	-0.68	-
Diluted Shares Outstanding	53.3M	54.1M	53.82M	53.69M	54.36M	61.68M	55.51M	55.96M	56.45M	57.65M
Basic Shares Outstanding	50.76M	51.99M	52.41M	52.62M	53.1M	53.67M	54.54M	55.1M	56.45M	57.65M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

SUPN Balance Sheet

Supernus Pharmaceuticals, Inc. (SUPN) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	228.45M	493.49M	472.64M	630.42M	601.59M	734.15M	493.11M	686.07M	644.18M	731.58M
Cash & Short-Term Investments	140.04M	356.02M	347.07M	422.53M	339.68M	461.33M	254.87M	453.61M	308.67M	384.24M
Cash Only	100.3M	192.25M	181.38M	288.64M	203.43M	93.12M	75.05M	69.33M	128.45M	184.87M
Short-Term Investments	39.74M	163.77M	165.69M	133.89M	136.25M	368.21M	179.82M	384.28M	180.22M	199.37M
Accounts Receivable	65.59M	102.92M	87.33M	140.88M	148.93M	165.5M	144.16M	142.08M	187.8M	182.18M
Days Sales Outstanding	79.21	91.87	81.16	98.81	93.76	90.53	86.61	78.36	95.34	80.12
Inventory	16.3M	25.66M	26.63M	48.33M	85.96M	91.54M	77.41M	54.29M	82.39M	87.06M
Days Inventory Outstanding	391.12	609.89	583.39	336.24	417.99	383.08	337.24	254.37	403.3	325.15
Other Current Assets	6.52M	8.89M	0	0	0	15.78M	16.68M	36.09M	65.33M	78.09M
Total Non-Current Assets	196.01M	484.32M	687.64M	873.68M	1.09B	968.36M	784.56M	682M	808.47M	769.14M
Property, Plant & Equipment	5.12M	4.09M	17.07M	37.82M	16.95M	15.17M	13.53M	11.54M	10.53M	10.04M
Fixed Asset Turnover	58.98x	99.85x	23.01x	13.76x	34.19x	43.98x	44.90x	57.32x	68.27x	73.51x
Goodwill	0	0	0	77.91M	117.52M	117.02M	117.02M	117.02M	124.88M	120.67M
Intangible Assets	36.02M	31.37M	24.84M	364.34M	784.69M	702.46M	599.89M	521.91M	569.46M	549.71M
Long-Term Investments	133.64M	418.8M	591.77M	350.36M	119.17M	93.9M	16.62M	0	0	0
Other Non-Current Assets	389K	380K	21.89M	43.25M	49.23M	39.81M	37.51M	31.53M	65.25M	223.79M
Total Assets	424.46M▲ 0%	977.81M▲ 130.4%	1.16B▲ 18.7%	1.5B▲ 29.6%	1.69B▲ 12.3%	1.7B▲ 0.8%	1.28B▼ 25.0%	1.37B▲ 7.1%	1.45B▲ 6.2%	1.5B▲ 0%
Asset Turnover	0.71x	0.42x	0.34x	0.35x	0.34x	0.39x	0.48x	0.48x	0.49x	0.54x
Asset Growth %	37.11%	130.36%	18.66%	29.63%	12.3%	0.79%	-24.95%	7.08%	6.18%	28.37%
Total Current Liabilities	123M	161.35M	160.59M	245.11M	315.38M	687.96M	290.2M	292.4M	338.17M	373.93M
Accounts Payable	6.84M	3.19M	10.14M	6.15M	9.33M	10.54M	1.96M	4.59M	2.68M	0
Days Payables Outstanding	164.18	75.94	222.18	42.77	45.37	44.12	8.56	21.49	13.1	132.68
Short-Term Debt	4.28M	2.18M	0	0	0	401.97M	0	0	0	0
Deferred Revenue (Current)	287K	-2.18M	0	0	0	0	0	0	0	0
Other Current Liabilities	17.03M	22.99M	14.47M	55.99M	93.04M	54.95M	77.08M	68.56M	98.72M	373.93M
Current Ratio	1.86x	3.06x	2.94x	2.57x	1.91x	1.07x	1.70x	2.35x	1.90x	1.90x
Quick Ratio	1.72x	2.90x	2.78x	2.37x	1.63x	0.93x	1.43x	2.16x	1.66x	1.66x
Cash Conversion Cycle	306.15	625.82	442.37	392.28	466.38	429.49	415.3	311.24	485.53	272.59
Total Non-Current Liabilities	33.98M	363.44M	404.27M	514.14M	557.92M	128.35M	65.96M	39.94M	52.76M	49.99M
Long-Term Debt	22.26M	329.46M	345.17M	361.75M	379.25M	0	0	0	0	30.27M
Capital Lease Obligations	0	0	30.44M	48.81M	41.3M	36M	33.2M	27.38M	30.36M	86.17M
Deferred Tax Liabilities	14.96M	31.46M	0	35.22M	85.36M	49.81M	24.96M	4.96M	0	0
Other Non-Current Liabilities	10.58M	33.97M	28.66M	68.36M	52.02M	42.54M	7.8M	7.6M	22.4M	57.92M
Total Liabilities	156.98M	524.79M	564.85M	759.24M	873.3M	816.3M	356.16M	332.34M	390.93M	423.92M
Total Debt	26.54M	329.46M	378.44M	414.32M	427.03M	444.76M	41.53M	34.27M	40.98M	30.27M
Net Debt	-73.76M	137.21M	197.05M	125.69M	223.59M	351.64M	-33.53M	-35.06M	-87.47M	-154.6M
Debt / Equity	0.10x	0.73x	0.64x	0.56x	0.52x	0.50x	0.05x	0.03x	0.04x	0.04x
Debt / EBITDA	0.25x	2.17x	2.38x	2.16x	3.60x	3.38x	0.52x	0.21x	0.75x	1.06x
Net Debt / EBITDA	-0.69x	0.91x	1.24x	0.66x	1.88x	2.67x	-0.42x	-0.22x	-1.60x	-1.60x
Interest Coverage	63.48x	7.98x	7.50x	8.10x	4.12x	9.59x	2.15x	-	-	-
Total Equity	267.48M▲ 0%	453.02M▲ 69.4%	595.43M▲ 31.4%	744.86M▲ 25.1%	815.85M▲ 9.5%	886.2M▲ 8.6%	921.52M▲ 4.0%	1.04B▲ 12.4%	1.06B▲ 2.5%	1.08B▲ 0%
Equity Growth %	39.49%	69.37%	31.43%	25.1%	9.53%	8.62%	3.98%	12.39%	2.51%	22.32%
Book Value per Share	5.02	8.37	11.06	13.87	15.01	14.37	16.60	18.51	18.81	18.68
Total Shareholders' Equity	267.48M	453.02M	595.43M	744.86M	815.85M	886.2M	921.52M	1.04B	1.06B	1.08B
Common Stock	51K	52K	53K	53K	53K	54K	55K	56K	57K	58K
Retained Earnings	-26.82M	86.49M	199.55M	326.5M	379.92M	481.25M	482.56M	556.43M	517.88M	515.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-747K	-3.16M	7.42M	8.97M	1.54M	-3.21M	-593K	-189K	-44K	-255K
Minority Interest	0	0	0	0	0	0	0	0	0	0

SUPN Cash Flow Statement

Supernus Pharmaceuticals, Inc. (SUPN) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	114.64M	128.99M	143.13M	138.4M	127.13M	116.83M	111.08M	171.95M	47.33M	47.33M
Operating CF Margin %	37.93%	31.54%	36.44%	26.59%	21.93%	17.51%	18.29%	25.98%	6.58%	-
Operating CF Growth %	71.59%	12.51%	10.96%	-3.3%	-8.14%	-8.1%	-4.91%	54.79%	-72.47%	-88.77%
Net Income	57.28M	110.99M	113.06M	126.95M	53.42M	60.71M	1.32M	73.86M	-38.55M	-29.02M
Depreciation & Amortization	8.13M	7.06M	6.66M	18.14M	32.59M	85.54M	84.86M	80.41M	90.03M	164.28M
Stock-Based Compensation	8.43M	11.29M	14.85M	16.56M	17.91M	17.57M	26.76M	27.75M	33.05M	56.86M
Deferred Taxes	21.22M	-4.17M	-5.83M	568K	-4.99M	-26.32M	-25.71M	-20.14M	5.21M	1.31M
Other Non-Cash Items	-4.14M	8.54M	13.79M	12.69M	24.62M	3.57M	33M	12.11M	32.75M	13.32M
Working Capital Changes	23.71M	-4.73M	613K	-36.52M	3.57M	-24.24M	-9.14M	-2.05M	-75.16M	-89.06M
Change in Receivables	-24.06M	-35.86M	15.75M	-34.61M	3.87M	-16.37M	18.77M	2.08M	-22.3M	-13.12M
Change in Inventory	497K	-9.36M	-969K	-10.12M	-14.58M	-17.86M	6.11M	15.81M	-7.5M	-10.42M
Change in Payables	-620K	-3.58M	6.96M	8.27M	18.18M	-19.16M	-36.29M	-15.02M	-24.57M	-28.45M
Cash from Investing	-86.42M	-413.48M	-157.92M	-34.7M	-81.91M	-216.66M	268.73M	-189.87M	4.11M	-52.43M
Capital Expenditures	-2.03M	-844K	-2.74M	-3.45M	-2.04M	-412K	-551K	-725K	-1.34M	-1.92M
CapEx % of Revenue	0.67%	0.21%	0.7%	0.66%	0.35%	0.06%	0.09%	0.11%	0.19%	-
Acquisitions	0	0	0	-313.54M	-311.69M	-14K	0	0	-293.09M	-293.09M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-11.15M	-809K	1.35M	-241K	12.89M	14K	0	9K	-439K	-348.93M
Cash from Financing	5.68M	376.44M	3.93M	3.56M	-130.42M	-10.48M	-397.88M	12.19M	9.13M	39.64M
Debt Issued (Net)	0	309.6M	0	-802K	-137.51M	0	-402.5M	0	0	0
Equity Issued (Net)	5.68M	11.58M	3.93M	4.36M	7.09M	12.42M	6.61M	14.91M	37.62M	35.57M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	0	55.25M	0	0	0	-22.9M	-1.99M	-2.71M	-28.49M	4.07M
Net Change in Cash	33.91M▲ 0%	91.94M▲ 171.2%	-10.87M▼ 111.8%	107.26M▲ 1087.0%	-85.21M▼ 179.4%	-110.31M▼ 29.5%	-18.07M▲ 83.6%	-5.72M▲ 68.3%	60.57M▲ 1158.3%	70.47M▲ 0%
Free Cash Flow	112.61M▲ 0%	128.14M▲ 13.8%	140.39M▲ 9.6%	134.95M▼ 3.9%	125.08M▼ 7.3%	116.41M▼ 6.9%	110.53M▼ 5.1%	171.23M▲ 54.9%	45.99M▼ 73.1%	82.25M▲ 0%
FCF Margin %	37.26%	31.34%	35.75%	25.93%	21.57%	17.45%	18.19%	25.87%	6.4%	10.59%
FCF Growth %	72.69%	13.79%	9.56%	-3.88%	-7.31%	-6.93%	-5.05%	54.91%	-73.14%	-49.65%
FCF per Share	2.11	2.37	2.61	2.51	2.30	1.89	1.99	3.06	0.81	0.81
FCF Conversion (FCF/Net Income)	2.00x	1.16x	1.27x	1.09x	2.38x	1.92x	84.41x	2.33x	-1.23x	-2.83x
Interest Paid	134K	1.34M	2.52M	2.52M	2.52M	2.52M	1.95M	0	0	0
Taxes Paid	1.59M	34.77M	51.54M	45.43M	25.19M	16.2M	36.6M	53.25M	0	15.51M

SUPN Key Ratios

Supernus Pharmaceuticals, Inc. (SUPN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	24.95%	30.81%	21.57%	18.94%	6.85%	7.13%	0.15%	7.55%	-3.68%	-2.73%
Return on Invested Capital (ROIC)	49.85%	27.64%	16.12%	15.67%	6.76%	3.04%	-0.37%	6.49%	-2.8%	-2.8%
Gross Margin	94.97%	96.24%	95.76%	89.92%	87.05%	86.93%	86.21%	88.23%	89.63%	89.42%
Net Margin	18.95%	27.14%	28.79%	24.39%	9.21%	9.1%	0.22%	11.16%	-5.36%	-3.74%
Debt / Equity	0.10x	0.73x	0.64x	0.56x	0.52x	0.50x	0.05x	0.03x	0.04x	0.04x
Interest Coverage	63.48x	7.98x	7.50x	8.10x	4.12x	9.59x	2.15x	-	-	-
FCF Conversion	2.00x	1.16x	1.27x	1.09x	2.38x	1.92x	84.41x	2.33x	-1.23x	-2.83x
Revenue Growth	40.57%	35.29%	-3.95%	32.5%	11.41%	15.09%	-8.95%	8.94%	8.63%	16.29%

SUPN SEC Filings & Documents

Supernus Pharmaceuticals, Inc. (SUPN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Apr 22, 2026·SEC

Material company update

Apr 7, 2026·SEC

10-K Annual Reports

FY 2026

Mar 2, 2026·SEC

FY 2025

Feb 25, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 5, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 5, 2025·SEC

SUPN Frequently Asked Questions

Supernus Pharmaceuticals, Inc. (SUPN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Supernus Pharmaceuticals, Inc. (SUPN) reported $776.8M in revenue for fiscal year 2025. This represents a 8639% increase from $8.9M in 2008.

Supernus Pharmaceuticals, Inc. (SUPN) grew revenue by 8.6% over the past year. This is steady growth.

Supernus Pharmaceuticals, Inc. (SUPN) reported a net loss of $29.0M for fiscal year 2025.

Dividend & Returns

Supernus Pharmaceuticals, Inc. (SUPN) has a return on equity (ROE) of -3.7%. Negative ROE indicates the company is unprofitable.

Supernus Pharmaceuticals, Inc. (SUPN) generated $82.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More SUPN

Supernus Pharmaceuticals, Inc. (SUPN) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Supernus Pharmaceuticals, Inc.(SUPN)Earnings, Financials & Key Ratios

SUPN Key Insights

✓Strengths

✗Weaknesses

SUPN Price & Volume

SUPN Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

SUPN Recent Earnings

SUPN Peer Comparison

Compare SUPN vs Peers

vs PCRX

vs MCK

Compare Top 5

SUPN Income Statement

SUPN Balance Sheet

SUPN Cash Flow Statement

SUPN Key Ratios

SUPN SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

SUPN Frequently Asked Questions

Explore More SUPN

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation